Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Amortization of Deferred Charges (2016 - 2023)

Historic Amortization of Deferred Charges for Cartesian Therapeutics (RNAC) over the last 9 years, with Q3 2023 value amounting to -$78000.0.

  • Cartesian Therapeutics' Amortization of Deferred Charges fell 13939.39% to -$78000.0 in Q3 2023 from the same period last year, while for Jun 2024 it was -$78000.0, marking a year-over-year decrease of 10859.98%. This contributed to the annual value of $455000.0 for FY2023, which is 5225.6% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Amortization of Deferred Charges of -$78000.0 as of Q3 2023, which was down 13939.39% from $135000.0 recorded in Q2 2023.
  • Cartesian Therapeutics' Amortization of Deferred Charges' 5-year high stood at $398000.0 during Q1 2023, with a 5-year trough of -$78000.0 in Q3 2023.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $196000.0 (2022), whereas its average is $181157.9.
  • In the last 5 years, Cartesian Therapeutics' Amortization of Deferred Charges soared by 31400.0% in 2021 and then crashed by 13939.39% in 2023.
  • Cartesian Therapeutics' Amortization of Deferred Charges (Quarter) stood at $64000.0 in 2019, then surged by 234.38% to $214000.0 in 2020, then fell by 0.93% to $212000.0 in 2021, then dropped by 16.98% to $176000.0 in 2022, then plummeted by 144.32% to -$78000.0 in 2023.
  • Its Amortization of Deferred Charges stands at -$78000.0 for Q3 2023, versus $135000.0 for Q2 2023 and $398000.0 for Q1 2023.